By proceeding, you agree to our Terms of Use and Privacy Policy.
GemPharmatech Co. Ltd., founded in 2017, is an international biotechnology enterprise specializing in the development of humanized animal models. The management and operation team has nearly 20 years of experience in gene-editing technology and animal production. GemPharmatech provides a one-stop service as model customization, breeding, phenotyping, and pharmacology for the biomedical research community. The company has developed the world's most abundant mouse strains resource to inspire scientific innovation and drive drug discovery.
12-14 July 2022
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models – Deepen Our Understanding of Tumor Biology, Resistance Mechanisms & Dosing Strategy Following the success of KRAS, HER2, BCMA, drug developers ha
Event Ended
USA
Paid
Boston
20-22 September 2022
The Newly Re-Branded 13th World Multispecifics Summit is the Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- & Multi-Specific Therapeutics With more clinical candidates and commercial success than ever within this rapidly
29-30 September 2022
Gain valuable insights into the approaches impacting the immunotherapy field through 40+ outstanding presentations tackling key discussion points in immuno-oncology, immunology and inflammation.Benefits to Attending... Gain a forward-looking perspect
UK
London
03-04 October 2022
Featuring 40+ presentations, the event brings together over 300 attendees from leading pharma, biotech and academic organisations designing innovative strategies and technologies for more effective cancer immunotherapy development. The Congress inclu
San Diego
07-08 December 2022
With next generation of complex immuno-oncology candidates, preclinical and translational scientists in the IO space are in need for more predictive tumour models to improve clinical translatability, accelerating speed-to-clinic with confidence.
28-30 March 2023
Dedicated to driving cost-effective, efficacious, safe, durable, scalable, and globally accessible allogeneic, cell-based, and engager therapies, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics.
28-30 June 2023
Join the 8th Microbiome Movement Drug Development Summit, an event that brings together top drug developers and technology enablers to advance the field of microbiome drug development. With a focus on cutting-edge science, preclinical and clinical tr
12-13 July 2023
The past year has seen several combination therapies entering Phase I and II clinical trials, with some showing promising results while others facing challenges, especially in the treatment of solid tumors. The FDA Modernization Act 2.0 has encourage